Soaring pipeline portfolio by leading drug makers to address the growing burden of dementia associated with Alzheimer’s disease is accounted to render significant growth impetus in foreseeable future. Substantial investments towards R&D initiatives and growing mindfulness amongst patients about advanced therapeutics further bolster growth. However, pricy treatments and prevalence of severe side effects remain notable loopholes that restrict growth in ... Read more
